Acetylon Pharmaceuticals has leased 9,700 square feet of headquarters office and lab space at Seaport Center in Boston.

Acetylon, which focuses on the discovery and development of potential drug candidates based on next-generation Class II-selective HDAC inhibitors, is the first R&D lab tenant in Seaport Center.

The new space on the second floor will include a combination of office and R&D laboratory space and two "biosafety level 2" labs. Construction is currently underway, and the project is set to be completed this summer. The company will be moving from 609 Albany St. in Boston.

Jones Lang LaSalle Managing Directors Bill Barrack and Ben Heller, and Associate Ben Hux served as brokers representing the landlord. McPherson Corp.’s Keith Coulter represented Acetylon. Seaport Center is now 80 percent leased. There are approximately 90,000 square feet of contemporary office, data center and lab space available.

Seaport Center is a 465,000-square-foot first class office building located at 70 Fargo St. in the South Boston Seaport District. It is directly across from the Westin Hotel and the Boston Convention Center, one block from the waterfront with direct access to the Ted Williams Tunnel.

"The building’s superior infrastructure and the ownership’s deal making prowess were pivotal factors in the transaction," said Heller. "The Innovation District has become a hotbed for life science companies. Seaport Center is well positioned for the future."

Jones Lang LaSalle is the exclusive leasing agent for Seaport Center. Margulies Perruzzi Architects has been selected to provide design services for the new office and lab space. Wise Construction Corp. is the construction manager for the project, and RDK Engineers is providing mechanical, electrical and plumbing engineering.